Global Information
회사소개 | 문의 | 비교리스트

리슈마니아증(칼라아자르) : 파이프라인 리뷰

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 192676
페이지 정보 영문 133 Pages
가격
US $ 2,000 ₩ 2,478,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,957,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,436,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


리슈마니아증(칼라아자르) : 파이프라인 리뷰 Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 133 Pages

리슈마니아증이란 사람이 모래파리에 물렸을 때 옮은 기생충에 의해 발병하는 감염증입니다. 주요 증상으로 체중 감소 및 혈구수 감소, 간·비장의 비대화, 발열 등을 들 수 있습니다. 주요 치료제에는 항기생충제 등이 있습니다.

세계 각국에서의 리슈마니아증(흑열병) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업의 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

리슈마니아증(칼라아자르) 개요

치료제 개발

  • 리슈마니아증용 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

리슈마니아증 치료제 개발에 참여하고 있는 기업

  • Advinus Therapeutics Ltd
  • BioLingus AG
  • Daiichi-Sankyo
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Matinas BioPharma Holdings Inc
  • Nanomerics Ltd
  • Novartis AG
  • Oblita Therapeutics BVBA

약제 개요

리슈마니아증 치료제 : 개발이 휴지 상태인 제품

리슈마니아증 치료제 : 개발이 중지된 제품

리슈마니아증 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향·프레스 릴리스

부록

도표

KSA 17.06.27

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by ABIONYX Pharma SA, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Acea Biotech Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Biokawthar Technologies SAS, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by DetectoGen Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Eurofins Advinus Ltd, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Immune Modulation Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SL, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Macrophage Therapeutics Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Mind Medicine Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Molecular Targeting Technologies Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Mycosynthetix Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by NanoCliq LLC, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Pai Life Sciences Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Pfizer Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Pharos I&BT Co Ltd, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Phi Pharma SA, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Rakta Therapeutics Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Sequella Inc, H2 2019
  • Leishmaniasis (Kala-Azar) - Pipeline by Synstar Japan Co Ltd, H2 2019
  • Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2019
  • Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2019, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 14, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3, 14 and 11 molecules, respectively.

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Leishmaniasis (Kala-Azar) - Overview
  • Leishmaniasis (Kala-Azar) - Therapeutics Development
  • Leishmaniasis (Kala-Azar) - Therapeutics Assessment
  • Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
  • Leishmaniasis (Kala-Azar) - Drug Profiles
  • Leishmaniasis (Kala-Azar) - Dormant Projects
  • Leishmaniasis (Kala-Azar) - Discontinued Products
  • Leishmaniasis (Kala-Azar) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q